Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mesoblast Limited
  6. Summary
    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
09/09/2021 09/10/2021 09/13/2021 09/14/2021 09/15/2021 Date
1.695 1.69 1.685 1.72 1.7 Last
2406274 1968493 1200550 3785606 1429466 Volume
-4.24% -0.29% -0.30% +2.08% -1.16% Change
Estimated financial data (e)
Sales 2022 40,7 M 29,8 M 29,8 M
Net income 2022 -113 M -82,7 M -82,7 M
Net cash position 2022 22,3 M 16,3 M 16,3 M
P/E ratio 2022 -8,01x
Yield 2022 -
Sales 2023 87,0 M 63,6 M 63,6 M
Net income 2023 -100 M -73,5 M -73,5 M
Net Debt 2023 - - -
P/E ratio 2023 -9,44x
Yield 2023 -
Capitalization 1 102 M 807 M 806 M
EV / Sales 2022 26,5x
Capi. / Sales 2023 12,7x
Nbr of Employees 83
Free-Float 85,6%
More Financials
Company
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL... 
More about the company
Ratings of Mesoblast Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about MESOBLAST LIMITED
09/02Australian shares rise on miners, energy boost
RE
09/02BHP : Australian shares end at 2-week low as BHP tumbles on ex-div trade
RE
09/01MESOBLAST : OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE YEAR ENDED JUNE..
PU
09/01Australia shares trim losses on better-than-expected GDP data
RE
09/01NOVARTIS : Mesoblast Deal On Cell Therapy Drags As US FDA Raises Manufacturing C..
MT
08/31Banks, miners drive Australian shares lower ahead of GDP data
RE
08/31Health Care Stocks Add to Early Slide
MT
08/31Health Care Stocks Slipping Tuesday
MT
08/31MESOBLAST : Health Care
MT
08/31MESOBLAST : Jefferies Downgrades Mesoblast to Hold From Buy
MT
08/31Wall Street Wavers Pre-Bell, Data in Focus
MT
08/31SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Tuesday
MT
08/31MESOBLAST : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Mainta..
MT
08/31MESOBLAST : Fiscal Year Revenue Declines
MT
08/31Tech, healthcare help Australia shares notch 2-week closing high
RE
More news
News in other languages on MESOBLAST LIMITED
09/01L'accord entre Novartis et Mesoblast sur la thérapie cellulaire traîne en lon..
08/31Les actions du secteur de la santé accentuent leur chute
08/31Les actions du secteur de la santé en baisse mardi
08/31Soins de santé
08/31Baisse des revenus de Mesoblast pour l'exercice fiscal
More news
Analyst Recommendations on MESOBLAST LIMITED
More recommendations
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast Limited Technical Analysis Chart | MSB | AU000000MSB8 | MarketScreener
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,70 AUD
Average target price 2,75 AUD
Spread / Average Target 61,8%
EPS Revisions
Managers and Directors
Silviu Itescu Chief Executive Officer, MD & Executive Director
Andrew Chaponnel Chief Financial Officer & Head-Finance
Joseph R. Swedish Independent Non-Executive Chairman
Fred Grossman Chief Medical Officer
Dagmar Rosa-Bjorkeson Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MESOBLAST LIMITED-24.44%807
MODERNA, INC.315.87%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.44.30%49 541
CELLTRION, INC.-24.09%31 848
SEAGEN INC.-13.16%27 670